Gergely5 showed that troponin comprises three protein subunits and that one of these, troponin C (TnC), binds calcium and is responsible for regulating the process of thin filament activation during skeletal muscle contraction. During the past 25 years, a large body of research has helped to further define the roles of Ca24 and TnC in controlling thin filament activation in cardiac and skeletal muscle. Most of these studies have used classic protein biochemistry in conjunction with biophysical techniques in an attempt to elucidate the structure of TnC and the mechanisms by which Ca24 binding to TnC facilitates contractility. Although this work has greatly expanded our knowledge of the biochemical bases of contractility, the recent cloning of the TnC complementary DNAs (cDNAs) and genes has made it possible, for the first time, to apply powerful molecular biological methods to studies of TnC structure, function, and regulation.
The purpose of this review is to summarize the current state of knowledge concerning the structure, function, and regulation of the TnC genes and proteins. This is not intended to be an exhaustive review of TnC biology and biochemistry but rather a critical overview of this field with particular emphasis on previous contributions and the future potential of molecular biology. (Given the large volume of prior research in this area, it is impossible to cite all of the contributors to the field; we apologize for any unintentional omissions of citation. For additional discussions of the structure and function of the TnC proteins, the reader is referred to several recent reviews. [6] [7] [8] [9] [10] Anatomy of the Sarcomere An understanding of the anatomy of the contractile apparatus in skeletal and cardiac muscle has provided the foundation on which to build models of the molecular mechanisms underlying contractility. The basic building block of the contractile apparatus is the sarcomere. This multisubunit structure is composed of a precise geometric arrangement of myosin-containing thick filaments surrounded by an hexagonal array of thin filaments, each of which contains actin and the troponin/tropomyosin (TM) regulatory complex (reviewed in Reference 7). The actin monomers within each thin filament are organized in a double-helical structure with one troponinTM complex associated with each repeat of seven actin monomers ( Figure 1 ).
Each troponinTM complex contains four distinct polypeptides: TnC, troponin I (TnI), troponin T (TnT), and TM, with a stoichiometry of 1:1:1:1.5,11 TnC is the 18-kD Ca24 binding subunit of the complex. Tnl is the 21-kD inhibitory subunit that prevents contraction in the absence of Ca24 and TnC. TnT (30 kD) is responsible for binding the troponin subunits to TM, a 66-kD protein that links the troponin complex to the actin helix. TM exists in the thin filament as a dimer composed of two 33 -kD subunits that are organized as a two-strand coiled coil. These TM coils are in turn arranged into long filaments formed by the head-to-tail overlap of TM dimers. The TM filaments are located in the groove of the actin helix with each 66-kD TM molecule contacting seven actin monomers. The troponin complex (TnC plus TnI plus TnT) displays an elongated conformation with TnC and TnI forming a globular head and TnT forming a rodlike tail12 ( Figure  1 ). Each troponin complex is bound to TM in an antiparallel fashion such that the NH2-terminal tail portion of TnT binds to the head-to-tail overlap region of TM, and the globular head binds to amino acids (aa) 150-180 of TM located almost 200 A away. 13 11 C T, troponin complex (Figure 2 ).16-18 Fast skeletal troponin C (sTnC) is a 160-aa polypeptide that is expressed exclusively in mammalian fast skeletal muscle. 19 Slow, or cardiac, troponin C (cTnC) is a 161-aa protein that is expressed in neonatal fast and slow skeletal and cardiac muscle. In the adult, the expression of the cTnC isoform is usually restricted to cardiac and slow skeletal muscle. 18 As described below, the two TnC isoforms are encoded by distinct single-copy mammalian genes. 20 22 The important function of these proteins is underscored by the finding that they have been highly conserved during 250 million years of evolution. The murine sTnC and cTnC proteins are more than 95% identical to their chicken homologues. 20, 21, 23, 24 The TnC proteins belong to a multigene family of Ca' binding proteins (reviewed in Reference 25) . Third, aa 50-60 from helix C in the NH2-terminal domain of sTnC also bind to the inhibitory peptide of TnI (aa 104-115). This binding appears to require occupancy of the low-affinity Ca2+ binding sites, suggesting that this interaction may play a role in transmitting the activation signal across the thin filament during muscle cell depolarization (see "Molecular Models of Ca2+-Activated Contraction," below).
Last, there is some evidence that suggests an interaction between aa 1-21 of TnI and an undefined region of TnC. 36 The structures of the regions of TnC (aa 50-60 and 90-100) and TnI (aa 104-115) that have been shown to interact in a Ca2+-dependent fashion have suggested a mechanism for their interaction. As first described by Grabarek et al,37 both regions of TnC form a-helices that contain acidic faces. The inhibitory peptide of TnI contains a large number (six of 12) of basic residues. Thus, it has been suggested that electrostatic interactions between these regions are responsible for their associations.
TnC-TnT Interactions
Recent cross-linking studies have also examined the interaction of sTnC with TnT in either heterodimeric complexes or trimeric complexes that also contained TnI.46 These studies demonstrated an interaction between Cys98 of TnC (located in the COOH-terminal half of the molecule) and residues 175-178 of TnT (Met-Lys-Lys-Lys). As described above, this same region of TnC (aa 90-100) has been shown to be closely associated with the inhibitory peptide of TnI. Interestingly, complexes composed of all three molecules (TnC, TnI, and TnT) contained both peptide combinations, indicating that this single region of TnC (aa 90-100) interacts with both TnI and TnT in a noncompetitive manner. Finally, it is important to note that the inhibitory peptide of Tnl (aa 104-115) has also been shown to interact directly with actin. 36, 38 The picture that has emerged from this large group of studies is one in which a relatively small number of conserved regions in the TnC and TnI proteins are involved in functionally important interactions with each other as well as with additional thin filament components. Thus, basic residues of the inhibitory peptide of Tnl (aa 104-115) appear to interact electrostatically with two distinct acidic a-helical regions of TnC (aa 50-60 and 90-100) as well as with actin. Similarly, a single region of TnC (aa 90-100) appears to interact with both the inhibitory peptide of Tnl and a basic region of the TnT molecule (aa 175-178). The importance of these interactions in regulating thin filament activation is discussed in more detail below. quenced. In agreement with previously published protein sequence data, cTnC and sTnC are 161-and 160-aa polypeptides that have been remarkably highly conserved during vertebrate evolution. Comparison of the aa sequences of the murine sTnC and cTnC proteins revealed that they are 70% identical21 (Figure 2 ). Despite this relatively high degree of sequence conservation, three areas of the two proteins display significant levels of diversity (less than 50% aa sequence identity). aa 1-18 (33% identity) comprise the NH2-terminal a-helical regions of the molecules. The function of these regions remains unknown. aa [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] (42% identity) constitute lowaffinity Ca2' binding site I. This site has been shown previously to be nonfunctional in cTnC. Finally, aa 117-131 (26% identity) constitute an a-helical region located between Ca>2 binding sites III and IV that may be involved in the interaction between TnC and TnI. The identification of these divergent regions of TnC should facilitate the design of in vitro mutagenesis and domain-swapping experiments aimed at elucidating the structural bases underlying the differences in sTnC and cTnC functions.
During the past 2 years, the human22 and murine21 sTnC genes and the murine cTnC gene20 have been isolated and characterized. The two TnC genes are remarkably similar in overall structure ( Figure 5 ). The murine sTnC gene comprises six exons spanning 2.6 kb of genomic DNA,2' whereas the murine cTnC gene comprises six exons spanning approximately 3.4 kb pairs.20 Interestingly, with the exception of the border between exon 1 and intron 1, the intron-exon borders of the two genes are similar or identical, both to each other and to those that divide the rat62 and chicken63 calmodulin genes and the rat64 parvalbumin genes. It is worth noting that the introns of sTnC and cTnC do not divide the gene into functional domains but rather are randomly dispersed throughout the four Ca2 binding loops. Kretsinger25 speculated that all of the genes in the TnC superfamily evolved from a single primordial Ca2 binding domain that subsequently underwent double intragenic duplication, resulting in four potential Ca2 binding sites in TnC. The finding that the introns of the sTnC and cTnC genes interrupt the four Ca2' binding loops at distinct sites and that the position of these introns has been conserved in most of the members of the TnC supergene family suggests that the members of this family evolved by duplication and subsequent diversification of a common ancestral gene that con- demonstrated that the murine C2C12 myoblast cell line can be used as a model system to study the developmental regulation of sTnC and cTnC gene expression during embryonic skeletal muscle development. Specifically, Northern-blot analyses demonstrated that C2C12 myoblasts do not express detectable cTnC or sTnC messenger RNAs. However, after 2 days of differentiation in medium containing low serum and growth to confluence (which results in the fusion of the myoblasts into myotubes), the expression of both genes was induced by more than 100-fold. Transient transfections of the C2C12 myoblasts and myotubes with reporter plasmids containing various regions of the sTnC and cTnC genes linked to the bacterial chloramphenicol acetyl transferase gene allowed the identification of the cis-acting sequences in the sTnC and cTnC genes that are responsible for these developmentally regulated patterns of expression. These experiments demonstrated that the sTnC and cTnC promoters (i.e., the 5' flanking sequences) were both inactive in C2C12 myoblasts and myotubes (Reference 21 and M. Parmacek, A. Vora, and J.
Leiden, unpublished results). High-level sTnC and cTnC gene expression in C2C12 myotubes was instead controlled by transcriptional enhancers located within the first introns of both genes ( Figure 6 ). These enhancers functioned in both position-and (Figure 6 ) (M. Parmacek, A. Vora, and J. Leiden, unpublished results). Thus, these studies allowed us to conclude that cTnC gene expression in skeletal muscle is controlled by a developmentally regulated, musclespecific enhancer within the first intron of the gene. This enhancer contains at least three nuclear protein binding sites, each of which is important for its activity. It is noteworthy that the enhancer does not appear to contain binding sites for the MyoD family of transcription factors.7677 Thus, either there is a non-MyoD pathway that regulates the expression of some skeletal muscle-specific genes or MyoD family members activate other transcription factors that then upregulate the expression of the cTnC gene. We are currently in the process of fully characterizing the muscle cell proteins that bind to these sites. Studies of the expression of these proteins during the transition from embryonic to adult skeletal muscle may also allow the elucidation of the molecular mechanisms responsible for the suppression of cTnC gene expression during this developmental transition.
As described above, cTnC is also expressed throughout the lifetime of the cardiac myocyte. To determine whether the same cis-acting sequences regulate cTnC gene expression in embryonic fast skeletal and neonatal cardiac muscle, we transfected chloramphenicol acetyl transferase reporter constructs containing cTnC regulatory sequences into primary neonatal rat cardiac myocytes and compared their activities with those observed in the C2C12 skeletal myotubes as described above. In contrast to what was observed in the C2C12 cells, the 5' flanking region of the cTnC gene (bp, -124 to +35) contains all of the sequences required for high-level cTnC expression in cardiac muscle ( Figure 6) Ca2' sensitivity and that this property is a result of an alteration in the troponin/TM regulatory complex in these fibers.78 79 It remains unclear which component of the complex is abnormal in these fibers, and it should be noted that sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses revealed no differences in the mobility of cTnC isolated from normal and cardiomyopathic hearts. 78 Previous studies have demonstrated that the genes encoding different isoforms of several myofibrillar proteins are differentially regulated in response to a variety of pathophysiological stimuli.80-82 For example, the rat ,B-myosin heavy chain gene, which is not expressed in normal ventricular myocytes, is induced by pressure overload.80 This raises the possibility that the sTnC gene, which is not normally expressed in ventricular myocytes, might also be inappropriately expressed in cardiac muscle in some pathophysiological states. Inappropriate expression of sTnC in the heart might be of clinical relevance if, as suggested by some investigators, sTnC was unable to mediate the Starling properties normally subserved by cTnC (see "cTnC and the Starling Properties of Cardiac Muscle," above).57 It should be emphasized that no evidence has been accumulated to suggest that sTnC is expressed in the heart. However, it is interesting that cTnC has been shown to be reexpressed in adult rabbit fast skeletal muscle after chronic low-frequency electrical stimulation in vivo. 83 The potential pathophysiological effects of sTnC expression in cardiac myocytes should be at least in part clarified by structural and functional studies of transgenic mice that express various ratios of sTnC and cTnC in cardiac muscle (see "cTnC and the Starling Properties of Cardiac Muscle," above).
The animal and human sera after myocardial ischemia and infarction. Such antibodies might also prove useful as tools for nuclear imaging of areas of myocardial infarction.
Because cTnC plays such a central role in regulating cardiac contraction, it is an excellent target for therapeutic approaches aimed at increasing myocardial performance in congestive heart failure. In particular, drugs that increase the affinity of low-affinity Ca2' binding site II in cTnC might be capable of increasing contractility in the failing myocardium.
Recent reports have suggested that bepridil, a Ca2' channel blocker, is able to bind to the NH2-terminal region of cTnC and thereby cause an increase in the Ca2' binding affinity of site 11.86 A structural understanding of this interaction might allow the synthesis of additional drugs that are able to modify the Ca2'-cTnC interaction in such a way as to produce sustained increases in myocardial contractility.
Summary and Future Directions During the past 10 years, significant progress has been made toward understanding the structure, function, and regulation of cardiac and skeletal TnC. The elucidation of the crystal structure of sTnC, the identification of the sites of interaction between TnC and TnI, the isolation of the TnC cDNAs and genes, and the characterization of the cis-acting sequences that regulate TnC gene expression during skeletal and cardiac myogenesis all represent particularly significant contributions to this field. As is true of all exciting areas of investigation, these discoveries have raised as many questions as they have answered. Thus, the next 10 years promise to provide further significant advances in our understanding of TnC function and regulation. Several areas stand out as particularly promising avenues of investigation. A more complete understanding of the structure of both sTnC and cTnC in solution (compared with the structure of crystals formed at nonphysiological pH) both alone and in combination with other thin filament proteins should greatly advance our understanding of TnC function. The use of in vitro mutagenesis techniques to produce variant recombinant TnC proteins for use in in vitro biochemical assays, skinned myocyte systems, and radiographic, crystallographic, and nuclear magnetic resonance studies promises to be a powerful system with which to dissect TnC function. Such studies may ultimately provide an accurate model of the conformational changes in TnC and the other thin filament proteins that result in Ca2'-mediated thin filament activation.
In addition, transgenic mouse systems may prove very useful for understanding the role of TnC in cardiac pathophysiology. Finally, studies of the trans-acting factors or nuclear proteins that regulate sTnC and cTnC expression during myogenesis may help to elucidate the molecular mechanisms that regulate skeletal and cardiac muscle development. Although much of this research is quite basic in nature, it appears likely that it will also result in a number of clinically relevant applications; these might include a better understanding of the molecular mechanisms underlying acquired and inherited cardiomyopathies, diagnostic tests for myocardial injury, and the development of rational therapies for heart failure.
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